Yesterday Onxeo announced its first preclinical proof-of-concept data with AsiDNA demonstrating the potential to be administrated intravenously. AsiDNA, a first-in-class DNA repair inhibitor, has already been tested in a Phase I trial with melanoma patients and showed promising results in terms of safety and initial signs of efficacy administered via local injection. After Onxeo acquired the drug in February 2016, the company repositioned the development and now seeking to establish a pre-clinical dossier to start human trials with intravenous injection, which would vastly increase the addressable indications. Yesterday’s announcement was the first substantial step in this direction, as Onxeo showed that AsiDNA was effective alone or in combination with carboplatin in murine models of triple negative breast cancer (TNBC).
